Informações:
Falhas:
ID
37421
Descrição
Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02305758
Link
https://clinicaltrials.gov/show/NCT02305758
Palavras-chave
Versões (1)
- 24/07/2019 24/07/2019 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
24 de julho de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Untreated Metastatic Colorectal Cancer NCT02305758
Eligibility Untreated Metastatic Colorectal Cancer NCT02305758
- StudyEvent: Eligibility
Similar models
Eligibility Untreated Metastatic Colorectal Cancer NCT02305758
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Adenocarcinoma of colon metastatic | Adenocarcinoma of rectum metastatic
Item
histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum
boolean
C4324497 (UMLS CUI [1])
C0149978 (UMLS CUI [2,1])
C1522484 (UMLS CUI [2,2])
C0149978 (UMLS CUI [2,1])
C1522484 (UMLS CUI [2,2])
Lesion unresectable Quantity | Measurable lesion CT scan
Item
at least 1 unresectable lesion on a ct (computerized tomography) scan that is measurable as defined by recist, version 1.1
boolean
C0221198 (UMLS CUI [1,1])
C1519810 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C1513041 (UMLS CUI [2,1])
C0040405 (UMLS CUI [2,2])
C1519810 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C1513041 (UMLS CUI [2,1])
C0040405 (UMLS CUI [2,2])
ECOG performance status
Item
ecog (eastern cooperative oncology group) performance score of 0 or 1
boolean
C1520224 (UMLS CUI [1])
Hematologic function | Renal function | Liver function
Item
adequate hematologic, renal and hepatic function
boolean
C0221130 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
Cancer treatment Colorectal cancer metastatic
Item
prior anti-cancer treatment for metastatic colorectal cancer
boolean
C0920425 (UMLS CUI [1,1])
C0948380 (UMLS CUI [1,2])
C0948380 (UMLS CUI [1,2])
Exposure to Poly(ADP-ribose) Polymerase Inhibitors
Item
prior exposure to parp (poly adp-ribose polymerase) inhibitors
boolean
C0332157 (UMLS CUI [1,1])
C1882413 (UMLS CUI [1,2])
C1882413 (UMLS CUI [1,2])
Adjuvant Chemotherapy Completed | Status pre- Colorectal cancer recurrent
Item
the last course of adjuvant chemotherapy must have ended > 12 months prior to colorectal cancer recurrence
boolean
C0085533 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0332152 (UMLS CUI [2,1])
C0854750 (UMLS CUI [2,2])
C0205197 (UMLS CUI [1,2])
C0332152 (UMLS CUI [2,1])
C0854750 (UMLS CUI [2,2])
Medical condition Major Uncontrolled
Item
any clinically significant and uncontrolled major medical condition
boolean
C3843040 (UMLS CUI [1,1])
C0205164 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
C0205164 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
Pregnancy | Breast Feeding
Item
participant is pregnant or lactating
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Medical condition High risk of Toxicities
Item
any medical condition, which in the opinion of the study investigator, places the participant at an unacceptably high risk for toxicities
boolean
C3843040 (UMLS CUI [1,1])
C0332167 (UMLS CUI [1,2])
C0600688 (UMLS CUI [1,3])
C0332167 (UMLS CUI [1,2])
C0600688 (UMLS CUI [1,3])
bevacizumab
Item
for those receiving bevacizumab, standard medical exclusionary conditions apply
boolean
C0796392 (UMLS CUI [1])